Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0Q8UU
|
||||
| Former ID |
DIB007469
|
||||
| Drug Name |
BM-17.0744
|
||||
| Synonyms |
K-111; 12-(4-Chlorophenyl)-2,2-dichlorododecanoic acid
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Type 1 diabetes [ICD9: 250; ICD10:E10] | Discontinued in Phase 2 | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C18H25Cl3O2
|
||||
| Canonical SMILES |
C1=CC(=CC=C1CCCCCCCCCCC(C(=O)O)(Cl)Cl)Cl
|
||||
| InChI |
1S/C18H25Cl3O2/c19-16-12-10-15(11-13-16)9-7-5-3-1-2-4-6-8-14-18(20,21)17(22)23/h10-13H,1-9,14H2,(H,22,23)
|
||||
| InChIKey |
GPCJDSXBRMKASP-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Peroxisome proliferator activated receptor alpha | Target Info | Activator | [2], [3] | |
| KEGG Pathway | PPAR signaling pathway | ||||
| cAMP signaling pathway | |||||
| Adipocytokine signaling pathway | |||||
| Glucagon signaling pathway | |||||
| Non-alcoholic fatty liver disease (NAFLD) | |||||
| Hepatitis C | |||||
| Pathway Interaction Database | RXR and RAR heterodimerization with other nuclear receptor | ||||
| Reactome | RORA activates gene expression | ||||
| BMAL1:CLOCK,NPAS2 activates circadian gene expression | |||||
| PPARA activates gene expression | |||||
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | |||||
| Transcriptional activation of mitochondrial biogenesis | |||||
| Activation of gene expression by SREBF (SREBP) | |||||
| Transcriptional regulation of white adipocyte differentiation | |||||
| Nuclear Receptor transcription pathway | |||||
| Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) | |||||
| Circadian Clock | |||||
| WikiPathways | Nuclear Receptors in Lipid Metabolism and Toxicity | ||||
| Nuclear Receptors Meta-Pathway | |||||
| Estrogen Receptor Pathway | |||||
| PPAR Alpha Pathway | |||||
| Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) | |||||
| Transcriptional Regulation of White Adipocyte Differentiation | |||||
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | |||||
| Activation of Gene Expression by SREBP (SREBF) | |||||
| Adipogenesis | |||||
| SREBF and miR33 in cholesterol and lipid homeostasis | |||||
| Circadian Clock | |||||
| Nuclear Receptors | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011739) | ||||
| REF 2 | Cardiac function and metabolism in Type 2 diabetic mice after treatment with BM 17.0744, a novel PPAR-alpha activator. Am J Physiol Heart Circ Physiol. 2002 Sep;283(3):H949-57. | ||||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.